| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Gilead Sciences, Inc. (GILD) has 11 insiders with recent SEC Form 4 filings, including 0 buys and 16 sells. GILD is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 626.3K | $79.13M | -15,000 | |
| Other | 46.9K | $5.93M | - | |
| Other | 46.6K | $5.89M | - | |
| VP | 44.2K | $5.58M | - | |
| Other | 27.9K | $3.52M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Apr 3, 2019 | Cogan John Francis | Director | Sale+OE | 2,700 | $66.74 | $180,198.00 | -4.7% | |
| Apr 1, 2019 | Whitley Richard James | Director | Sale+OE | 9,534 | $65.48 | $624,254.86 | -27.5% | |
| Mar 27, 2019 | Cogan John Francis | Director | Sale+OE | 2,700 | $64.14 | $173,178.00 | -4.7% | |
| Mar 20, 2019 | Cogan John Francis | Director | Sale+OE | 2,700 | $65.07 | $175,689.00 | -4.7% | |
| Feb 19, 2019 | Wilson Gayle E | Director | Sale+OE | 19,068 | $67.08 | $1,279,073.81 | -13.3% | |
| Dec 3, 2018 | Martin John C | Director | Sale+OE | 50,000 | $71.20 | $3,560,178.15 | -0.6% | |
| Nov 1, 2018 | Martin John C | Director | Sale+OE | 50,000 | $69.55 | $3,477,617.30 | -0.5% | |
| Oct 1, 2018 | Martin John C | Director | Sale+OE | 50,000 | $78.04 | $3,902,209.79 | -0.8% | |
| Sep 4, 2018 | Martin John C | Director | Sale+OE | 50,000 | $74.16 | $3,708,033.84 | -0.8% | |
| Aug 1, 2018 | Martin John C | Director | Sale+OE | 50,000 | $77.85 | $3,892,650.00 | -1.6% |